Paul Peter Tak

Translational medicine can be defined as the continuum from a scientific idea or a finding through to a diagnostic tool and/or therapy applied to human diseases. The field of translational medicine encompasses molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among other disciplines. Translational Medicine has emerged as a discipline central to the goal of converting basic science discoveries to diagnostic and therapeutic tools that can be harnessed to treat disease and improve human health. The Vision, Mission and Strategy Of The Eureka Institute >Our vision is to develop translational medicine to address unmet medical needs. >Our mission is to build and foster a global community of translational medicine professionals for the tangible benefit of patients and society as a whole. >Our overall strategy is to catalyze, integrate and impact education, research and policymaking in an international translational medicine ecosystem that benefits society.

Translational medicine can be defined as the continuum from a scientific idea or a finding through to a diagnostic tool and/or therapy applied to human diseases. The field of translational medicine encompasses molecular medicine, intellectual property, financing, regulation, preclinical and clinical trial studies, among other disciplines. Translational Medicine has emerged as a discipline central to the goal of converting basic science discoveries to diagnostic and therapeutic tools that can be harnessed to treat disease and improve human health. The Vision, Mission and Strategy Of The Eureka Institute >Our vision is to develop translational medicine to address unmet medical needs. >Our mission is to build and foster a global community of translational medicine professionals for the tangible benefit of patients and society as a whole. >Our overall strategy is to catalyze, integrate and impact education, research and policymaking in an international translational medicine ecosystem that benefits society.

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism. Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.